Federal regulators have documented at least 30 patients who experienced adverse events after receiving compounded intravenous glutathione, with reactions spanning fever, rigors, hypotension, shock-like presentations, and sepsis-like syndromes. The primary driver in the most recent cluster is elevated endotoxin contamination traced to dietary supplement-grade raw material used in sterile compounding — a practice the FDA explicitly prohibits.
What Is the Regulatory Timeline of Federal Warnings About Injectable Glutathione?
The FDA issued its first compounding risk alert on injectable glutathione in February 2019, warning against dietary supplement-grade Letco Medical powder in sterile preparations. A second alert in August 2019 linked at least 30 adverse events to Medisca Inc. Lot #229536. The CDC opened a multistate investigation in 2025, and a third wave of pharmacy recalls occurred in late 2026.
The February 2019 FDA alert was triggered by reports of seven patients who experienced adverse events after receiving a compounded 200 mg/mL IV glutathione preparation. All seven cases were traced to glutathione raw material labeled as dietary supplement grade — a specification that does not meet the purity, sterility, or endotoxin-testing requirements for parenteral drug manufacturing.
The August 2019 FDA reminder expanded the scope considerably. At least 30 patients across multiple compounding pharmacies experienced adverse events, all of which sourced their glutathione from a single Medisca Inc. lot. The FDA explicitly noted that dietary supplement-grade ingredients lack the pharmaceutical-grade quality controls required for injectables.
By 2025, the CDC had opened a multistate investigation into illnesses linked to compounded glutathione injections, advising healthcare providers to halt administration of any product compounded from dietary supplement-grade starting material. In October 2026, Tomball, Texas-based Greenwich Rx issued a voluntary nationwide recall of specific compounded glutathione lots due to elevated endotoxin levels, with two patients requiring emergency care.
What Is the Full Spectrum of Adverse Events Documented in the Clinical Literature?
Documented adverse events range from mild infusion reactions — nausea, dizziness, headache, and injection-site pain — to life-threatening presentations including hypotension, shock, and systemic inflammatory response syndrome (SIRS). A 2025 case report in PMC describes a patient who developed SIRS with hyperpyrexia exceeding 41°C and cardiovascular collapse within one hour of receiving a high-dose glutathione-containing IV product.
The CDC's current advisory lists the following reactions as characteristic of contaminated glutathione injection exposure: fever, chills, body aches, headache, nausea, and low blood pressure. The agency notes that reactions can be severe and may require emergency medical care. These symptoms are consistent with endotoxin-mediated pyrogenic responses rather than direct glutathione toxicity.
Sharma et al. (2025, PMC12185258) reported a previously healthy woman who presented with SIRS shock and hyperpyrexia above 41°C within an hour of receiving Glutax 75GX DCRP, an unregulated high-dose IV glutathione product. The patient was concurrently using tirzepatide, and the authors note that nutritional compromise associated with GLP-1 receptor agonist use may heighten vulnerability to endotoxin-mediated inflammatory cascades.
Johnstone et al. (2018, Epidemiology and Infection) documented seven cases of probable endotoxin poisoning linked to contaminated compounded glutathione infusions. Five of the seven patients were using the infusions for cosmetic skin-lightening purposes. Clinical presentations included rigors, fever, and hypotension consistent with endotoxaemia.
Why Does Endotoxin Contamination Occur in Compounded Glutathione Products?
Endotoxin contamination in compounded glutathione arises when dietary supplement-grade raw material — manufactured without pharmaceutical-grade bacterial endotoxin testing (BET) — is used to prepare sterile injectables. Gram-negative bacterial lipopolysaccharides present in the raw powder survive standard sterilisation filtration and trigger TLR4-mediated inflammatory cascades when introduced intravenously.
Pharmaceutical-grade APIs intended for parenteral use must meet USP bacterial endotoxin limits, calculated as 5 EU/kg/hour for intravenous administration under USP <797>. Dietary supplement-grade glutathione is manufactured under food-grade or nutraceutical GMP standards, which impose no endotoxin limits whatsoever. This creates a structural quality gap that filtration alone cannot close.
Endotoxins are lipopolysaccharide fragments from the outer membrane of Gram-negative bacteria. They are heat-stable and pass through 0.22 µm sterilising filters intact. Once administered intravenously, LPS binds to TLR4 receptors on monocytes and macrophages, triggering TNF-α, IL-1β, and IL-6 release — the cytokine cascade responsible for the fever, hypotension, and shock presentations documented in the glutathione adverse event reports.
The FDA's 2019 alerts and the subsequent recalls all share a common thread: the implicated pharmacies obtained their glutathione from ingredient suppliers whose products were labeled for dietary supplement use, not for sterile injectable compounding. The Medisca Lot #229536 implicated in the 30-patient cluster and the lots recalled by Optimal Balance Pharmacy, Victory Medical Center Pharmacy, and Greenwich Rx in 2026 all involved this ingredient-grade mismatch.
Which Specific Products and Pharmacies Have Been Subject to Recalls?
At least four compounding pharmacies have issued voluntary nationwide recalls of compounded glutathione 200 mg/mL multi-dose vials due to elevated endotoxin levels: Optimal Balance Pharmacy, Victory Medical Center Pharmacy, Greenwich Rx (October 2026), and a fourth Texas-area pharmacy under CDC investigation. All recalled products were 503A-compounded preparations distributed to clinics and wellness providers.
Optimal Balance Pharmacy and Victory Medical Center Pharmacy both issued voluntary nationwide recalls of compounded glutathione 200 mg/mL multi-dose vials citing elevated endotoxin levels. Both pharmacies are Texas-based 503A compounders. The FDA recall notices confirm the endotoxin exceedance as the basis for withdrawal.
Greenwich Rx, a 503A compounding pharmacy based in Tomball, Texas, issued a voluntary nationwide recall on October 1, 2026, covering specific lots of compounded glutathione injections. The recall was triggered after two patients required emergency care following administration of the product. The FDA recall notice confirms elevated endotoxin levels as the cause.
The pattern across all recalls is consistent: multi-dose vials compounded at 503A pharmacies, distributed to wellness clinics and aesthetic medicine providers, and administered intravenously for purposes including skin lightening, antioxidant therapy, and general wellness — none of which represent FDA-approved indications for any compounded glutathione product.
What Safety Considerations Apply to Practitioners Administering or Considering Injectable Glutathione?
Practitioners must verify that any compounded glutathione injectable was prepared from pharmaceutical-grade API with documented bacterial endotoxin testing results, not from dietary supplement-grade raw material. The FDA, CDC, and multiple state boards of pharmacy have issued explicit guidance that dietary supplement-grade glutathione must not be used in sterile injectable preparations under any circumstances.
The FDA's current position, reiterated across multiple compounding risk alerts, is unambiguous: glutathione intended for dietary supplement use must not be used to compound injectable drugs. Compounders sourcing ingredients must confirm that the supplier's certificate of analysis includes BET results meeting USP parenteral limits, and that the material was manufactured under pharmaceutical-grade GMP — not nutraceutical or food-grade GMP.
Clinicians administering compounded glutathione IVs should be aware that no compounded glutathione product has FDA approval for any indication. The compound is not on the FDA's 503A or 503B bulk drug substances lists as of 2026, meaning its compounding exists in a regulatory grey zone with no formal federal approval pathway. Adverse event reporting to MedWatch is mandatory when reactions occur.
Patients who have received compounded glutathione injections and experience fever, rigors, hypotension, or other systemic symptoms within hours of administration should seek emergency evaluation. The differential diagnosis must include endotoxin-mediated SIRS, sepsis from microbial contamination, and anaphylaxis. Clinicians should retain the implicated vial for testing and report to the FDA MedWatch system and the relevant state board of pharmacy.
What Evidence Gaps Prevent a Complete Safety Assessment of Compounded Glutathione Injectables?
The adverse event record for compounded glutathione injectables derives almost entirely from spontaneous reports, case series, and recall investigations rather than prospective pharmacovigilance. No controlled safety study of compounded glutathione has been conducted. The true incidence of adverse events is unknown because most wellness-clinic administrations occur outside hospital settings where systematic reporting is absent.
The FDA's adverse event database (FAERS) captures only a fraction of actual adverse events — estimates for spontaneous reporting systems suggest under-reporting rates of 90–99% for non-serious events. For a compound administered primarily in aesthetic and wellness clinic settings, the reporting gap is likely at the higher end of that range. The 30-patient figure cited in the FDA's 2019 alert almost certainly represents a small fraction of total reactions.
No pharmacokinetic study of intravenously administered glutathione has been completed in humans under controlled conditions. The optimal dose, infusion rate, and maximum tolerated concentration for IV glutathione are therefore undefined by any regulatory standard. This absence of pharmacokinetic data compounds the safety risk: clinicians administering the product have no evidence-based dose ceiling to reference. Which Peptides Could Exit the FDA's Compounding Restriction List After the July 2026 Advisory Vote? Why Did FDA Scientists Recommend Against Adding TB-500, BPC-157, and MOTS-C to the Compounding Greenlist in July 2026? What Does the FDA Panel's July 2026 Compounding Recommendation Mean for BPC-157, TB-500, and KPV When Human Efficacy Data Are Absent?